Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.
Bruel T, Pinaud L, Tondeur L, Planas D, Staropoli I, Porrot F, Guivel-Benhassine F, Attia M, Pelleau S, Woudenberg T, Duru C, Koffi AD, Castelain S, Fernandes-Pellerin S, Jolly N, De Facci LP, Roux E, Ungeheuer MN, Van Der Werf S, White M, Schwartz O, Fontanet A. Bruel T, et al. Among authors: jolly n. EClinicalMedicine. 2022 Jul 22;51:101576. doi: 10.1016/j.eclinm.2022.101576. eCollection 2022 Sep. EClinicalMedicine. 2022. PMID: 35891947 Free PMC article.
Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France.
Fafi-Kremer S, Bruel T, Madec Y, Grant R, Tondeur L, Grzelak L, Staropoli I, Anna F, Souque P, Fernandes-Pellerin S, Jolly N, Renaudat C, Ungeheuer MN, Schmidt-Mutter C, Collongues N, Bolle A, Velay A, Lefebvre N, Mielcarek M, Meyer N, Rey D, Charneau P, Hoen B, De Seze J, Schwartz O, Fontanet A. Fafi-Kremer S, et al. Among authors: jolly n. EBioMedicine. 2020 Sep;59:102915. doi: 10.1016/j.ebiom.2020.102915. Epub 2020 Jul 31. EBioMedicine. 2020. PMID: 32747185 Free PMC article.
A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations.
Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, Guivel-Benhassine F, Staropoli I, Chazal M, Dufloo J, Planas D, Buchrieser J, Rajah MM, Robinot R, Porrot F, Albert M, Chen KY, Crescenzo-Chaigne B, Donati F, Anna F, Souque P, Gransagne M, Bellalou J, Nowakowski M, Backovic M, Bouadma L, Le Fevre L, Le Hingrat Q, Descamps D, Pourbaix A, Laouénan C, Ghosn J, Yazdanpanah Y, Besombes C, Jolly N, Pellerin-Fernandes S, Cheny O, Ungeheuer MN, Mellon G, Morel P, Rolland S, Rey FA, Behillil S, Enouf V, Lemaitre A, Créach MA, Petres S, Escriou N, Charneau P, Fontanet A, Hoen B, Bruel T, Eloit M, Mouquet H, Schwartz O, van der Werf S. Grzelak L, et al. Among authors: jolly n. Sci Transl Med. 2020 Sep 2;12(559):eabc3103. doi: 10.1126/scitranslmed.abc3103. Epub 2020 Aug 17. Sci Transl Med. 2020. PMID: 32817357 Free PMC article.
SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020.
Fontanet A, Tondeur L, Grant R, Temmam S, Madec Y, Bigot T, Grzelak L, Cailleau I, Besombes C, Ungeheuer MN, Renaudat C, Perlaza BL, Arowas L, Jolly N, Pellerin SF, Kuhmel L, Staropoli I, Huon C, Chen KY, Crescenzo-Chaigne B, Munier S, Charneau P, Demeret C, Bruel T, Eloit M, Schwartz O, Hoen B. Fontanet A, et al. Among authors: jolly n. Euro Surveill. 2021 Apr;26(15):2001695. doi: 10.2807/1560-7917.ES.2021.26.15.2001695. Euro Surveill. 2021. PMID: 33860747 Free PMC article.
Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
Planchais C, Fernández I, Bruel T, de Melo GD, Prot M, Beretta M, Guardado-Calvo P, Dufloo J, Molinos-Albert LM, Backovic M, Chiaravalli J, Giraud E, Vesin B, Conquet L, Grzelak L, Planas D, Staropoli I, Guivel-Benhassine F, Hieu T, Boullé M, Cervantes-Gonzalez M, Ungeheuer MN, Charneau P, van der Werf S, Agou F; French COVID Cohort Study Group; CORSER Study Group; Dimitrov JD, Simon-Lorière E, Bourhy H, Montagutelli X, Rey FA, Schwartz O, Mouquet H. Planchais C, et al. J Exp Med. 2022 Jul 4;219(7):e20220638. doi: 10.1084/jem.20220638. Epub 2022 Jun 15. J Exp Med. 2022. PMID: 35704748 Free PMC article.
Unravelling the determinants of human health in French Polynesia: the MATAEA project.
Teiti I, Aubry M, Fernandes-Pellerin S, Patin E, Madec Y, Boucheron P, Vanhomwegen J, Torterat J, Lastère S, Olivier S, Jaquaniello A, Roux M, Mendiboure V, Harmant C, Bisiaux A, Rijo de León G, Liu D, Bossin H, Mathieu-Daudé F, Gatti C, Suhas E, Chung K, Condat B, Ayotte P, Conte E, Jolly N, Manuguerra JC, Sakuntabhai A, Fontanet A, Quintana-Murci L, Cao-Lormeau VM. Teiti I, et al. Among authors: jolly n. Front Epidemiol. 2023 Nov 27;3:1201038. doi: 10.3389/fepid.2023.1201038. eCollection 2023. Front Epidemiol. 2023. PMID: 38455935 Free PMC article.
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.
Launay O, Artaud C, Lachâtre M, Ait-Ahmed M, Klein J, Luong Nguyen LB, Durier C, Jansen B, Tomberger Y, Jolly N, Grossmann A, Tabbal H, Brunet J, Gransagne M, Choucha Z, Batalie D, Delgado A, Müllner M, Tschismarov R, Berghmans PJ, Martin A, Ramsauer K, Escriou N, Gerke C. Launay O, et al. Among authors: jolly n. EBioMedicine. 2022 Jan;75:103810. doi: 10.1016/j.ebiom.2021.103810. Epub 2022 Jan 16. EBioMedicine. 2022. PMID: 35045362 Free PMC article. Clinical Trial.
Mother-to-child transmission of human T-cell-leukemia/lymphoma virus type I: implication of high antiviral antibody titer and high proviral load in carrier mothers.
Ureta-Vidal A, Angelin-Duclos C, Tortevoye P, Murphy E, Lepère JF, Buigues RP, Jolly N, Joubert M, Carles G, Pouliquen JF, de Thé G, Moreau JP, Gessain A. Ureta-Vidal A, et al. Among authors: jolly n. Int J Cancer. 1999 Sep 9;82(6):832-6. doi: 10.1002/(sici)1097-0215(19990909)82:6<832::aid-ijc11>3.0.co;2-p. Int J Cancer. 1999. PMID: 10446450 Free article.
Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
Launay O, Sadorge C, Jolly N, Poirier B, Béchet S, van der Vliet D, Seffer V, Fenner N, Dowling K, Giemza R, Johnson J, Ndiaye A, Vray M, Sansonetti P, Morand P, Poyart C, Lewis D, Gougeon ML. Launay O, et al. Among authors: jolly n. Vaccine. 2009 Feb 18;27(8):1184-91. doi: 10.1016/j.vaccine.2008.12.021. Epub 2009 Jan 9. Vaccine. 2009. PMID: 19135496 Clinical Trial.
In a preliminary Phase 1 single dose prospective study, we showed that SC599 vaccine was well tolerated, and the maximum tolerable dose was greater than 10(8) CFU [Sadorge C, Ndiaye A, Beveridge N, Frazer S, Giemza R, Jolly N, et al. Phase 1 clinical trial of …
In a preliminary Phase 1 single dose prospective study, we showed that SC599 vaccine was well tolerated, and the maximum tolerable dose was …
128 results